Beijing Chunlizhengda Medical Instruments (HKG:1858) Third Quarter 2024 Results
Key Financial Results
- Revenue: CN¥128.2m (down 49% from 3Q 2023).
- Net loss: CN¥17.9m (down by 133% from CN¥54.5m profit in 3Q 2023).
- CN¥0.045 loss per share (down from CN¥0.14 profit in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Beijing Chunlizhengda Medical Instruments Earnings Insights
Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in Hong Kong.
Performance of the Hong Kong Medical Equipment industry.
The company's shares are down 2.9% from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. See our latest analysis on Beijing Chunlizhengda Medical Instruments' balance sheet health.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.